Company
Every investor coverage indicates participated in a round Shire plc raised.
Every published round Shire plc took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Shire plc has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Shire plc, as distinct from the investments it has made.
Companies Shire plc has backed that another company then bought. An exit for the holding, not a deal Shire plc did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| No portfolio company of Shire plc is recorded as having been acquired. | ||||
The transaction that ended Shire plc's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Takeda | Acquisition | 2018 | - | Brandon BioCatalyst, Brandon Capital |
Companies Shire plc acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Company | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Fibrotech | Acquisition | 2014 | US$75m ($85.6m) | Brandon BioCatalyst, Brandon Capital, Startup Daily (Wed 15 Nov 2023), Startup Daily (Thu 2 May 2019), Brandon BioCatalyst portfolio, Brandon Capital portfolio, anthillonline.com, GBS Ventures |
Stories naming Shire plc. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Certa Therapeutics has acquired OccuRx, combining two GPR68 fibrosis pipelines founded by Professor Darren Kelly, and says it will seek Series B funding to advance clinical development.
Uniseed adds Monash and a four-university NSW collaboration, lifting its third fund by $6.75 million to $56.75 million; the article recalls past portfolio sales to Novartis, Shire and Schneider Electric.
Brandon Capital's blog reports a first close of $210 million toward its $250 million MRCF 5 biotech fund, with super funds and CSL backing, and recalls past portfolio sales of Spinifex and Fibrotech.
Brandon Capital's Medical Research Commercialisation Fund has launched its fifth vehicle, MRCF5, completing a NZ$224 million first close and targeting NZ$267 million, while recalling earlier portfolio exits of Elastagen, Spinifex and Fibrotech.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Startup Daily
Venture fund Uniseed led a million-dollar slice of probiotic drinks maker PERKii's four-million-dollar round, its first deal from its new $50 million fund, to fund a national launch.
GBS Ventures reports Novartis has agreed to acquire chronic-pain drug developer Spinifex Pharmaceuticals for US$200 million upfront plus milestones, recalling the company's 2005, 2008 and 2014 venture rounds and its Australian investors.
Also GBS Ventures·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·novartis.com·clinicalleader.com·Brandon Capital portfolio·Startup Daily·Startup Daily·Startup Daily·anthillonline.com·@AuManufacturing·materresearch.org.au·Business News Australia